Abacus FCF Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
Abacus FCF Advisors's BMY Position: Q3 2026 in Review
Abacus FCF Advisors increased its Bristol-Myers Squibb (BMY) stake by 4.7% in Q3 2026, buying an estimated $680K and bringing the position to 238,336 shares worth $15M. The position accounts for 2.81% of the portfolio, ranked #8.
Abacus FCF Advisors first reported a position in BMY in Q2 2021 and has held it in 22 quarters since. The position peaked at $20.8M in Q4 2025. 2,569 funds tracked by Wall St. Rank hold BMY as of Q3 2026.
- Abacus FCF Advisors held 238,336 shares of Bristol-Myers Squibb worth $15M as of Q3 2026.
- Abacus FCF Advisors bought 10,752 Bristol-Myers Squibb shares in Q3 2026, an estimated $680K.
- Bristol-Myers Squibb made up 2.81% of Abacus FCF Advisors's portfolio in Q3 2026, its #8 holding.
- Abacus FCF Advisors first reported a position in Bristol-Myers Squibb in Q2 2021 and has held it in 22 quarters since.
- Abacus FCF Advisors's Bristol-Myers Squibb position peaked at $20.8M in Q4 2025.
- 2,569 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.
Based on Abacus FCF Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.